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AbstrAct
Olfactory ecto-mesenchymal stem cells (OE-MSCs) are a population of cells which 
has been recognized as a new resident stem cell type in the olfactory lamina propria. 
OE-MSCs have been shown to exert their immunosuppressive capacity by modulating 
T cell responses, including up-regulation of regulatory T cells (Tregs) and down-
regulation of Th1/Th17 cells. As an inflammatory cytokine, IL-17 plays a critical role in 
orchestrating the inflammatory response during the development of collagen-induced 
arthritis (CIA). However, it is unclear whether the increased level of IL-17 may affect 
the immunosuppressive function of OE-MSCs under inflammatory condition. In this 
study, we found that IL-17 could significantly reduce the suppressive capacity of 
OE-MSCs on CD4+ T cells and down-regulate the suppressive factors produced by 
OE-MSCs. Notably, IL-17 treatment abolished the capacity of OE-MSCs in inducing 
Treg expansion. In addition, knockdown of IL-17R in OE-MSCs significantly enhanced 
their therapeutic effect in ameliorating CIA upon adoptive transfer. Moreover, IL-
17R knockdown-OE-MSCs could efficiently induce Tregs expansion and reduce Th1 
and Th17 responses. Taken together, all these data suggest that IL-17R knockdown 
in OE-MSCs may provide a novel strategy in maintaining their immunosuppressive 
properties for the treatment of autoimmune diseases.
IntroductIon
Rheumatoid arthritis (RA) is an autoimmune disease 
caused by chronic joint inflammation, leading to cartilage 
destruction and bone erosion [1]. Although the precise 
etiology of RA is still elusive, various proinflammatory 
cytokines and autoreactive T cells are essential elements 
in its pathogenesis. The activation of Th1 cells and Th17 
cells has been considered to be critical factors in the 
pathogenisis of cell-mediated autoimmune arthritis [2, 
3]. In contrast, Treg cells and Th2 cells are protective in 
RA and in animal models of collagen-induced arthritis 
(CIA) [4, 5]. The development of therapies in RA 
treatment progressed slowly. Currently, although products 
such as IL-1 antagonists, TNF inhibitors and anti-IL-6 
receptor antibody are effective in RA treatment, not all 
the RA patients respond to these cytokine associated 
products, and none of these drugs are curative for RA [6]. 
Thereafter, novel strategies for RA treatment should be 
explored. Mesenchymal stem cells (MSCs) are multipotent 
progenitor cells, which can be isolated from bone 
marrow, cord blood, muscle and fat tissue. MSCs have 
the capability to differentiate into adipogenic, osteogenic, 
and chondrogenic lineages, and have the ability to 
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differentiate to lineages of mesenchymal tissues, including 
bone, cartilage and adipose tissues [7]. Moreover, MSCs 
have been considered to have potent immunosuppressive 
and anti-inflammatory effects via cell-cell contact or by 
secreting soluble factors, such as IL-10, NO, TGF-β, 
indoleamine 2, 3-dioxygenase (IDO), prostaglandin E2 
(PGE2) and so on [8, 9]. They effectively impair the 
proliferation or the activation of T cells, B cells, NK cells 
and antigen presenting cells, thus raising great interest 
for their potential therapeutic application. Accumulating 
experimental and clinical evidence has demonstrated that 
MSCs could lead to significant immunosuppressive effects 
when treating different inflammatory and autoimmune 
diseases [10, 11]. Recently, olfactory ecto-mesenchymal 
stem cells (OE-MSCs) have been recognized to be a new 
resident stem cell type in the olfactory lamina propria. 
OE-MSCs sited in nasal cavity, developing primarily from 
neural crest cells, possessing high proliferation rate, self-
renewal capability and multiple differentiation capability. 
Our previous work has demonstrated that OE-MSCs can 
exert their immunosuppressive capacity in modulating 
T cell responses and ameliorate disease severity in CIA 
mice [12]. Although the MSC-based immunotherapy has 
shown significant effect in CIA treatment, the application 
of MSCs in clinic still encounters different difficulties, 
such as some patients with autoimmune diseases are not 
sensitive to the MSCs treatment.
IL-17 has recently been implicated in the 
pathogenesis of various autoimmune diseases, including 
RA and the mouse model CIA. High level of IL-17 was 
found in the serum and synovial fluid of RA patients [13-
15]. Accumulating evidence has suggested that IL-17 is 
an essential pathogenic cytokine that is associated with 
autoimmune joint inflammation. Furthermore, IL-17 is 
reported to be one of the critical reasons leading to the 
failure of MSC-based immunotherapy, such as mouse 
colitis [15]. 
Although it is well known that OE-MSCs possess 
immunosuppressive effect, it is unclear whether IL-
17 will have negative regulation of OE-MSCs and then 
affect the effect of MSCs application, especially in 
diseases with high levels of IL-17 or the patients in the 
stage of high concentration of IL-17. To investigate it, we 
used IL-17 to stimulate OE-MSCs and found that IL-17 
could significantly reduce the suppressive effect of OE-
MSCs, and IL-17 treated OE-MSCs lost the capacity of 
promoting the expansion of Tregs. In addition, the IL-17R 
knockdown-OE-MSCs showed more efficient effect in 
treating CIA mouse when compared to the control OE-
MSCs, which suggests that at the peak of IL-17 during the 
CIA development, OE-MSCs might be regulated and then 
cause the failure of treatment. Thereafter, blocking the IL-
17/IL-17R pathway might be an effective strategy favors 
the OE-MSC clinical application.
results
Il-17 down-regulates the suppressive capacity of 
oe-Mscs
The OE-MSCs were successfully isolated from 
nasal cavity of mice and cultured as described in Materials 
and Methods. Flow cytometric analysis showed that OE-
MSCs expressed CD29, CD44, CD90 but not CD34, 
CD45, CD11b markers (Supplementary Figure 1A). In 
addition, OE-MSCs could differentiate into osteocytes 
and adipocytes (Supplementary Figure 1B), which 
suggests that OE-MSCs have similar phenotypic features 
and multiple-lineage differentiation capacities of MSCs. 
Next, to investigate the effect of IL-17 on OE-MSCs, we 
first examined whether OE-MSCs express IL-17R. Both 
flow cytometry analysis and RT-PCR showed that the 
OE-MSCs expressed IL-17R (Figure 1A, 1B). IL-17 is a 
pro-inflammatory cytokine whose level is increased during 
autoimmune diseases. In an effort to determine if IL-17 
treatment has any effect on the suppressive function of 
OE-MSCs in vitro, we co-cultured CD4+ T cells with OE-
MSCs treated with or without IL-17. As shown in Figure 
1C, compared to the non-treated OE-MSCs group, the 
suppression of OE-MSCs on CD4+ T cells was blocked 
in the IL-17-treated OE-MSCs group, and the status of 
cells in the co-culture system was also observed under the 
microscope (100×, Figure 1D), which suggests that the 
suppressive activity of OE-MSCs on CD4+ T cells was 
significantly inhibited by IL-17 stimulation. 
suppressive factors expressed by oe-Mscs are 
down-regulated upon Il-17 treatment
As PD-L1, NO, IL-10 and TGF-β are key factors 
in MSCs-mediated inhibition, we co-cultured CD4+ T 
cells with OE-MSCs treated with or without IL-17, and 
then analyzed mRNA levels and protein levels of these 
suppressive factors in OE-MSCs or IL-17-treated OE-
MSCs. In Figure 2A, mRNA levels of PD-L1, iNOS, IL-
10 and TGF-β were reduced after OE-MSCs stimulated 
with IL-17, and the protein levels of NO, IL-10 and TGF-β 
in the culture supernatants were also significantly down-
regulated in IL-17-stimulated OE-MSCs (Figure 2B).
Il-17 inhibits the expansion of tregs induced by 
oe-Mscs
It is acknowledged that MSCs could promote the 
expansion of CD4+CD25+Foxp3+ Treg cells [12]. To 
observe the capacity of IL-17-treated OE-MSCs to induce 
the expansion of Tregs, we co-cultured OE-MSCs with 
CD4+ T cells. As shown in Figure 3, the percentage of 
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CD4+CD25+Foxp3+ Treg cells was decreased in IL-17-
treated OE-MSCs group when compared to the OE-MSCs 
group, which indicates that IL-17 could block the capacity 
of OE-MSCs in inducing the expansion of Tregs.
Il-17r knockdown -oe-Mscs exhibits more 
efficient immunotherapeutic effect in CIA mice
IL-17 has recently been implicated in the 
pathogenesis of multiple autoimmune diseases, including 
RA and the mouse model CIA. We found that IL-17 in 
the serum of CIA mice was markedly increased on day 
14 after the first immunization, and reached its apogee 
on day 27 (Figure 4B). All mice developed long-lasting 
elevation of serum IL-17 even before they developed 
arthritis. Next, we sought to determine whether IL-17 
could regulate the function of OE-MSCs and affect the 
therapeutic effect of OE-MSCs in the treatment on CIA. 
Small interference RNA (siRNA) was used to knock down 
the IL-17R level in OE-MSCs. Adoptive transfer of OE-
MSCs or IL-17R siRNA treated OE-MSCs (siRNA IL-
17R OE-MSCs) into CIA mice were performed on day 
27 as the Figure 4A described. Then, the arthritis onset 
and disease progression were analyzed. As shown in 
Figure 4C and 4D, the clinical score was decreased and 
the development of arthritis was strikingly delayed in the 
siRNA IL-17R OE-MSCs group, whereas the OE-MSCs 
presented relative worse therapeutic effect under the 
environment with high concentration of IL-17. In addition, 
serum levels of anti-CII autoantibodies were significantly 
decreased in IL-17R siRNA treated OE-MSCs group than 
those in control groups, which was also slightly lower 
than OE-MSCs-treated mice (Figure 4E). Moreover, the 
swelling degree of the paws was significantly ameliorated 
in the siRNA IL-17R OE-MSCs treated mice (Figure 4F), 
and the histological analysis further showed significant 
improvement in the injury of joint (Figure 4G). Taken 
together, these data suggest that IL-17R siRNA treated 
OE-MSCs have more efficient effect on the treatment of 
CIA especially under the high level of IL-17 condition, 
which implies their great potential in RA treatment. 
Il-17r knockdown -oe-Mscs effectively reduce 
inflammatory responses in collagen-induced 
arthritis.
The clinical amelioration and histological 
verification in CIA mice strongly suggest that IL-17R 
Figure 1: Il-17 reduces the suppressive capacity of oe-Mscs. A. OE-MSCs were stained for IL-17R with anti-IL-17R antibody 
(thick line histogram) or rat IgG2a (solid gray histogram) and then analyzed using flow cytometry. b. RNA isolated from OE-MSCs was 
subjected to RT-PCR to measure IL-17R mRNA expression. c., d. OE-MSCs were stimulated with or without IL-17 (0, 10, 20, 50 ng/
ml) for 48 h, and then cells were harvested to co-cultured with CD4+ T cells in the presence of anti-CD3 mAb and anti-CD28 mAb for 72 
h. Suppression of T-cell proliferation was measured by [3H]-thymidine incorporation (C), and the status of cells in the co-culture system 
was also observed under the microscope (100×, D). Data are presented as mean ± SD pooled from three independent experiments. ***p < 
0.001, **p < 0.01.
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knockdown OE-MSCs are a potent tolerogenic agent 
that could suppress the autoimmune responses in CIA. 
We next investigated the mechanisms underlying the 
decrease in the severity of CIA. As shown in Figure 5A, 
the proportion of CD4+CD25+Foxp3+ Tregs in draining 
lymph nodes (dLN) was significantly increased after the 
IL-17R siRNA treated MSCs were injected in to the CIA 
mice, whereas the OE-MSCs treated group did not lead to 
the significant enhanced Tregs. Moreover, percentages of 
CD4+IFN-γ+Th1 cells (Figure 5B) and CD4+IL-17+Th17 
cells (Figure 5C) were decreased after siRNA IL-17R OE-
MSCs treatment. In addition, levels of proinflammatory 
cytokines IFN-γ and IL-17 were also down-regulated in 
the serum of CIA mice (Figure 5D, 5E). All these data 
indicate that during the treatment of CIA, OE-MSCs 
with IL-17R knocked down exhibit more efficient effect 
in reducing the inflammatory response by inducing the 
expansion of Tregs, thus reducing the Th1 and Th17 
responses and relevant inflammatory factors as compared 
to the OE-MSCs, especially in the high level of IL-17 
environment in vivo.
dIscussIon
Previous studies indicate that MSCs are 
increasingly being used to treat autoimmune and systemic 
inflammatory diseases [16, 17]. Although the detailed 
mechanism of MSC-based immune therapy has not been 
fully elucidated [18], bone marrow-derived MSCs might 
exert immunosuppressive properties by modulating T 
Figure 2: Il-17 down-regulates the suppressive factors of oe-Mscs. A., b. OE-MSCs were stimulated with or without IL-17 
(20 ng/ml) for 48 h, and then cells were harvested to co-culture with CD4+ T cells in the presence of anti-CD3 mAb and anti-CD28 mAb 
for 72 h, (A) and then OE-MSCs were collected to extract total RNA, and qRT-PCR was used to analyze the mRNA expression of PD-L1, 
iNOS, IL-10 and TGF-β, (B) and the supernatant was harvested to detect NO, IL-10 and TGF-β. Data are presented as mean ± SD pooled 
from three independent experiments. **p < 0.01, *p < 0.05.
Figure 3: Il-17 reduces the capacity of oe-Mscs in inducing the expansion of tregs. OE-MSCs were treated with or 
without IL-17 (20 ng/ml) for 48 h, and then cells were harvested to co-culture with CD4+ T cells in the presence of anti-CD3 mAb and anti-
CD28 mAb for 72 h, and then the proportion of CD4+CD25+Foxp3+ Treg cells in the co-culture system was analyzed by flow cytometry. 
Data are presented as mean ± SD pooled from three independent experiments. **p < 0.01, N.S represents no significance.
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cells [19]. Many studies have demonstrated that MSCs 
can suppress the activation and function of various cells 
of the innate and adaptive immune systems, including by 
modulating T and B cell proliferation and differentiation, 
dendritic cell maturation as well as NK activity [20]. It is 
reported that MSCs could induce the generation of Tregs 
from CD4+ or CD8+ T cells, and these Tregs have powerful 
immunosuppression that strongly inhibit lymphocytes [21, 
22]. Furthermore, MSCs have been also demonstrated to 
generate induced Tregs (iTregs) which could suppress 
effector T cells [23]. 
However, several recent reports showed 
that bone marrow-derived MSCs can be switched 
immunosuppression function by microbial molecular 
patterns through inflammatory cytokines [24]. MSCs can 
respond differently to different inflammatory stimuli [25]. 
MSCs acquire distinct immunophenotypes and activate 
different signaling pathways that may regulate immune 
responses. IL-17 is an inflammatory cytokine which 
is mainly produced by immune cells, such as Th17 and 
γδ T cells [26]. IL-17 is believed to play a critical role 
in orchestrating the inflammatory response in CIA [27, 
Figure 4: IL-17R knockdown OE-MSCs efficiently ameliorates the development of CIA. A. Graphic scheme of CIA 
induction and OE-MSCs administration. DBA/1J mice were immunized with CII/CFA on day 0 and boosted with CII/IFA on day 21. 
Treatment groups were intravenously injected with OE-MSCs (1×106) transfected with IL-17R siRNA or negative control on day 27 
after CII/CFA immunization. Mice were then sacrificed on day 42. b. IL-17 levels on day 0, day 14, day 27 and day 42 during the CIA 
development were detected by ELISA. c., d. Clinical score (C) and incidence of arthritis development (D) in immunized mice treated with 
OE-MSCs transfected with IL-17R siRNA or negative control were monitored every 3 days (n=6 per group). e. Serum levels of CII-specific 
autoantibodies from OE-MSCs transfected with IL-17R siRNA or negative control were detected by ELISA. F. Photos of hind paws from 
CIA mice treated with OE-MSCs transfected with IL-17R siRNA or negative control. G. Representative section of hind paws stained with 
hematoxylin and eosin, then assessed for histopathological scores of joint tissue from three groups. Results are expressed as mean ± SD. 
**p < 0.01,*p < 0.05, N.S represents no significance.
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28]. It was confirmed by reports showing that CIA was 
suppressed in IL-17-deficient mice and administration of 
neutralizing anti-IL-17 antibodies significantly reduced the 
severity of CIA [29]. Moreover, it has been demonstrated 
that serial serum IL-17 levels is increased after collagen 
immunization in CIA mice [27]. Therefore, our aim of 
this study was to investigate the effect of the inflammatory 
cytokine IL-17 on OE-MSCs, and then further explore the 
therapeutic effect of OE-MSCs on the rheumatoid arthritis 
under the environment with high level of IL-17.
Here we firstly showed that IL-17 could decrease the 
inhibitory capacity of OE-MSCs in suppressing effector 
T cell proliferation. Further investigation demonstrated 
that IL-17 decreased the suppressive ability of OE-MSCs 
mainly by down-regulating the levels of inhibitory factors 
produced by OE-MSCs, including soluble factors NO, 
IL-10, TGF-β as well as cell surface-expressed inhibitory 
molecule PD-L1. It has been reported that the downstream 
signaling of IL-17 involves several pathways, including 
NFκB, MAPK (p38/JNK/ERK) and C/EBP [30]. In 
addition, Yang et al have found that IL-17 produced by a 
subset of IL-17+ MSCs could down-regulate the level of 
Figure 5: Il-17r knockdown oe-Mscs enhances treg cells and reduces th1 and th17 cell responses in collagen-
induced arthritis. A., b., c. CD4+CD25+Foxp3+ Treg cells (A), CD4+IFN-γ+ Th1 (B) and CD4+ IL-17A+ Th17 (C) in the draining lymph 
nodes of CIA mice treated with OE-MSCs transfected with IL-17R siRNA or negative controls (n = 3/group). d., e. Serum levels of IFN-γ 
(D) and IL-17 (E) in CIA mice in these three groups were measured by ELISA. Results are expressed as mean ± SD. **p < 0.01,*p < 0.05. 
N.S represents no significance.
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TGF-β in MSCs via NFκB pathway [31]. Nevertheless, 
further studies are warranted to elucidate the molecular 
mechanism underlying the regulatory effect of IL-17 on 
the suppressive ability of OE-MSCs. 
Previous studies using bone marrow-derived MSCs 
in CIA model have generated conflicting results [32, 33]. 
Although more and more studies have shown that MSCs 
are “licensed” to exert their immunomodulatory effects 
after stimulation with IFN-γ in the presence of one or 
more other cytokine(s), including TNF, IL-1α or IL-1β, 
some other interesting studies also showed the opposite 
effect of MSCs after inflammatory stimulation [34, 35]. 
For instance, MSCs can provide a pro-inflammatory 
signature by the Toll-like receptor 4 activation [25]. 
These findings bring new insight to understanding of 
the crosstalk between MSCs and the inflammatory 
niche and provide practical information for improving 
the therapeutic potential of MSCs in the treatment of 
autoimmune diseases. Although IL-17 production has 
been demonstrated to increase in CIA, it was not known 
whether IL-17 had any effect on OE-MSCs during the 
treatment of CIA. Our studies have implicated that IL-17 
has a profound influence in the treatment effect of OE-
MSCs in CIA model. Compared with OE-MSCs, OE-
MSCs interfered with IL-17R exerted more potent anti-
proliferative activity and induced Treg expansion and 
decrease Th1 and Th17 cell generation in vivo, which 
might be attributed to the recovery of their capacity to 
produce high levels of IL-10, TGF-β and NO.
In summary, our study has demonstrated that IL-17 
obviously reversed the immunosuppressive function of 
OE-MSCs. Important for their clinical transformation is 
the fact that OE-MSCs maintain the immunosuppressive 
activity observed in vitro after their infusion in vivo. In 
our findings, therapy with siRNA IL-17R OE-MSCs has 
a highly beneficial method for specifically suppressing 
the immune response in CIA model. We believe that these 
results could help shape future clinical strategies for the 
treatment of autoimmune diseases.
MAterIAls And Methods
Isolation and culture of oe-Mscs
OE-MSCs were obtained from the nasal cavity 
by delicately discarding the turbinates and then cut the 
retained olfactory epithelium into small pieces and culture 
in flasks with the medium (Dulbecco’s modified Eagle’s 
medium (DMEM)/HAM’SF-12 supplemented with 15% 
fetal calf serum) (Gibco, Carlsbad, CA). One week later, 
non-adherent cells were removed and stem cells will begin 
to invade the culture flasks. After reached 80% confluency 
in the dish, adherent cells were trypsinized (0.05% trypsin-
ethylene-diaminetetraacetic acid at 37°C for 2 min) and 
expanded for 3 passages. 
osteogenic and adipogenic differentiation of oe-
Mscs
To assess the multipotentiality of OE-MSCs, cells 
were induced by osteogenic medium and adipogenic 
medium in vitro. The osteogenic induction medium 
was a mixture of MEM-supplemented with 0.1μM 
dexamethasone (SigmaAldrich, St.Louis, MO), 10 mM 
β-glycerol phosphate (SigmaAldrich, St.Louis, MO) and 
0.2 mM ascorbic acid (SigmaAldrich, St. Louis,MO). 
After 21 days, cells were subjected to alizarin red staining 
(Cyagen, Guangzhou, China). To induce adipogenic 
differentiation, OE-MSCs were cultured in mesenchymal 
stem cell adipogenic differentiation medium (Cyagen, 
Guangzhou, China). 14 days later, cells were subjected to 
oil red O staining (Cyagen, Guangzhou, China).
Mice
DBA1/J mice (8-10 weeks, male) were obtained 
from the Shanghai Laboratory Animal Center (Shanghai, 
China) and maintained in the Jiangsu University Animal 
Center (Jiangsu, China). All animal experiments were 
approved by the Jiangsu University Animal Ethics and 
Experimentation Committee.
Induction and assessment of arthritis
For CIA induction, we immunized male DBA/1J 
mice by injecting 100 μg of bovine type II collagen 
(Chondrex, WA, USA) emulsified with complete 
Freund’s adjuvant (C II:CFA=1:1, CFA: Sigma Aldrich, 
St. Louis, MO) via the base of the tail. 21 days later, a 
booster emulsion prepared by a boost with 100 μg of 
the same bovine collagen type II emulsified in Freund’s 
incomplete adjuvant (Sigma Aldrich, St.Louis, MO) near 
the primary injection site. To determine the effect of OE-
MSCs treatment, mice were received a single intravenous 
injection of 1×106 OE-MSCs or OE-MSCs treated with IL-
17R siRNA on day 24 after 1st immunization. From day 
21, mice were scored for signs of arthritis every 3 days. 
Each paw was evaluated and scored individually using a 
0 to 4 scoring system. The paw scores were summed to 
yield the clinical score, with a maximum score of 16 for 
each mouse. Each paw score was judged as follows: 0, 
no evidence of erythema and swelling; 1, erythema and 
mild swelling confined to the tarsals or ankle joint; 2, 
erythema and mild swelling extending from the ankle to 
the tarsals; 3, erythema and moderate swelling extending 
from the ankle to metatarsal joints; and 4, erythema and 
severe swelling encompass the ankle, foot and digits, or 
ankylosis of the limb [36]. The assessment was performed 
Oncotarget42960www.impactjournals.com/oncotarget
by 2 of the authors who were blinded to the identity of the 
specimens.
histopathologic analysis of the joints
After mice were sacrificed on day 42 after the 
first immunization, murine joint tissue specimens were 
obtained and fixed in 10% phosphate-buffered formalin for 
3 days. Tissue sections (4μm thickness) were stained with 
hematoxylin and eosin to examine morphologic features 
and assess the histologic arthritis score. The extent of 
synovitis, pannus formation, and bone/cartilage destruction 
was determined using a graded scale as follows: grade 
0, no signs of inflammation; 1, mild inflammation with 
hyperplasia of the synovial lining without cartilage 
destruction; 2, pannus formation and cartilage erosion; 3, 
major erosion of cartilage and subchondral bone; 4, loss 
of joint integrity and ankylosis [37, 38]. The assessment 
was performed by 2 of the authors who were blinded to the 
identity of the specimens.
co-culture of oe-Mscs and t cells
OE-MSCs were stimulated with or without IL-17 (0, 
10, 20, 50 ng/ml) for 48 h, and then cells were harvested 
to co-cultured with CD4+ T cells that were sorted from 
wild-type mice using CD4+ T cells microbeads (Miltenyi 
Biotec,Bergisch Gladbach, Germany) in the presence of 
anti-CD3 mAb (10mg/mL, Biolegend, SanDiego, CA) and 
anti-CD28 mAb (5mg/mL, Biolegend, San Diego, CA) 
for 72 h and then cells were pulsed with [3H]-thymidine 
(Pharmacia, Stockholm, Sweden, 1μCi/well) for the last 
16 h of culture. 
Flow cytometric analysis
To identify the OE-MSCs phenotype, single cell 
suspensions were stained with relevant fluorochrome-
conjugated mouse CD29, CD90, CD44, CD45, CD11b IL-
17R mAbs (eBioscience, San Diego, CA). For detection 
of regulatory T (Treg) cells, anti-CD4, anti-CD25, and 
anti-Foxp3 mAbs (eBioscience, San Diego, CA) were 
performed using Foxp3 staining buffer set (eBioscience, 
San Diego, CA). For intracellular cytokine staining, 
single cell suspensions were stimulated with phorbol 
myristateacetate (50ng/ml, SigmaAldrich, St.Louis, 
MO), ionomycin(1µg/ml, Enzo, Farmingdale, NY) and 
monensin (2 µg/ml, Enzo, Farmingdale, NY) at 37°C 
and in a 5% CO
2 
atmosphere for 5 hours. Then cells were 
stained with anti-CD4 mAbs (eBioscience, San Diego, 
CA), fixed, permeabilized and stained with anti-IFN-γ 
mAb or anti-IL-17 mAb (eBioscience, San Diego, CA). As 
controls, the appropriate isotype-matched antibodies were 
used for each staining. Flow cytometry was performed 
using a FACS Calibur flow cytometer (eBioscience,San 
Diego,CA), and the data was analyzed by WinMDI 2.8 
software.
Measurement of autoantibodies and cytokines
Serum levels of type II collagen-specific antibody 
were measured by enzyme-linked immunosorbentassay 
(ELISA) as previously described. Levels of IL-17, 
TGF-β, IFN-γ, IL-10 in culture supernatants or serum 
of murine samples were measured using ELISA Ready-
SET-Go Kits (eBioscience, San Diego, CA) following the 
manufacturer’s protocol. The amount of NO was assessed 
by determining the concentration of nitrite accumulated in 
culture supernatants using the colorimetric Griess reaction 
(Promega, Madison, WI).
Quantitative real-time Pcr (qrt-Pcr)
To determine gene expression, total RNA was 
extracted with TRIzol reagent (Invitrogen). Isolated 
total RNA was reversed-transcribed with ReverTra 
Ace qPCR RT kit (TOYOBO) according to the 
manufacturer’s instructions. The reverse transcript PCR 
and qRT-PCR were performed as described previously 
[39]. The sequences for the primers used are: IL-17R, 
5-AGTGTTTCCTCTACCCAGCAC-3 (forward), 
5-GAAAACCGCCACCGCTTAC-3 (reverse); TGF-β, 
5-AACCGGCCCTTCCTGCTCCTCAT-3 (forward), 
5-CGCCCGGGTTGTGTTGGTTGTAGA-3 (reverse); 
IL-10, 5-GGTTGCCAAGCCTTATCGGA-3(forward), 
5-ACCTGCTCCACTGCCTTGCT-3 (reverse); β-actin, 
5-TGGAATCCTGTGGCATCCATGAAAC-3 (forward), 
5-TAAAACGCAGCTCAGTAACAGTCCG-3 (reverse); 
iNOS, 5-GAGCCCTCAGCAGCATCCAT-3 (forward), 
5-GGTGAGGGCTTGGCTGAGTG-3 (reverse); 18s, 
5-TCCGGAGAGGGAGCCTGAGA-3 (forward), 
5-GCACCAGACTTGCCCTCCAA-3 (reverse); PD-
L1, 5-CTGCTTGCGTTAGTGGTGT-3 (forward), 
5-TGGTTGATTTTGCGGTATG-3 (reverse). Relative 
quantification of mRNA expression was calculated by the 
comparative threshold cycle (Ct) method. 
transfection
IL-17R siRNA was designed and synthesized by 
RiboBio Co. Ltd. Nonspecific scramble siRNA was used as 
negative control. OE-MSCs were transfected with IL-17R 
siRNA or negative control using Entranster-R (Engreen 
Biosystem) according to the manufacturers’ instructions 
[40]. The final concentration of oligonucleotides was 100 
nM. 
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statistics
The statistical significance of differences between 
groups was determined by the Student’s t test and one-
way analysis of variance. All analyses were performed 
using SPSS16.0 software. Differences were considered 
significant at a p level less than 0.05.
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